Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

Science

Technology Platform
Publications 


Scientific Publications

54. Ohana G, Cohen S, Rath-Wolfson L, Fishman P. A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. Mol Med Rep. 2016 Nov;14(5):4335-4341
53.
David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV, Cosgarea MR, Morariu HS, Michael Z, Cristodor P, Nica C, Silverman MH, Bristol DR, Harpaz Z, Farbstein M, Cohen S, Fishman P. Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial. J Drugs Dermatol. 15(8):931-8
52. Fishman P and Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol, 2016; 35(9):2359-62
51. Rumen M Stoilov, Rodina N Licheva, Mariyana K Mihaylova, Tatiana Reitblat, Emil A Dimitrov, Krasimira M Shimbova, Girish Bhatia, Ameet Pispati, Alexandra Gurman- Balbir, BR Bagaria, Boytcho Aleksandrov Oparanov, Sari Fishman, Zivit Harpaz, Motti Farbstein, Shira Cohen, David Bristol, Michael H Silverman and Pnina Fishman. Therapeutic Effect of Oral CF101 in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Phase II Study. Immunome Res 2014, 11:1
50. Pnina Fishman. Adenosine Receptors – The Promise of A3AR Research. Drug Development & Delivery March, 2015 Vol 15 No 1
49. Cohen S, Barer F, Bar-Yehuda S, IJzerman AP, Jacobson KA, Fishman P. A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. Mediators Inflamm. 2014;2014:708746. doi: 10.1155/2014/708746. Epub 2014 Oct 13
48. Pnina Fishman, Shira Cohen, Sara Bar Yehuda. Targeting the A3 adenosine receptor for glaucoma treatment (Review). Molecular Medicine Reports. DOI: 10.3892/mmr.2013.1413
47. Stemmer M, Benjaminov F, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study. The Oncologist. 18:25-26, 2013   Online version
46. Pnina Fishman, Sara Bar-Yehuda, Bruce T. Liang and Kenneth A. Jacobson. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17(7-8):359-66
45. Clara C. Blad, Jacobien K. von Frijtag Drabbe Künzel, Henk de Vries, Thea Mulder-Krieger, Sara Bar-Yehuda, Pnina Fishman, Adriaan P. IJzerman. Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine. Purinergic Signal, 2011
44. Sara Bar-Yehuda, Dror Luger, Avivit Ochaion, Shira Cohen, Renana Patokaa, Galina Zozulya, Phyllis B. Silver, Jose Maria Garcia Ruiz De Morales, Rachel R. Caspi, Pnina Fishman. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med. Nov;28(5):727-3, 2011
43. Ashar JN, Mathur A, Sangwan V. Avni I, Sliverman MH, Bar Yehuda S, Fishman P. CF101 for dry eye. Ophthalmology. 118:1011-1012, 2011
42. David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. Journal of the European Academy of Dermatology and Venereology, 2011
41. Cohen S, Stemmer SM,Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. Journal of Cellular Physiology, 226:2438-2447, 2011
40. I. Avni, H. Garzozi, I. Barequet, F. Segev, D. Varssano, G. Sartani, N. Chetrit, E. Bakshi, D. Zadok, O. Tomkins, G. Litvin, K. Jacobson, S Fishman, Z. Harpaz, M. Farbstein, S. Bar Yehuda, M. Silverman, W. Kerns, D. Bristol, I Cohn, P. Fishman. Treatment of Dry Eye Syndrome with Orally Administered CF101. Data from a Phase 2 Clinical Trial. Ophthalmology , 117:1287-1293, 2010
39. Fishman, P., Bar-Yehuda, S., Varani, K., Gessi, S., Merighi, S., and Borea, PA. Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. In: P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics. © Springer Science+Business Media B.V. 2010
38. Fishman, P., Bar-Yehuda, S. Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications. P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics. © Springer Science+Business Media B.V. 2010
37. S. Bar-Yehuda, L. Rath-Wolfson, L. Del Valle, A. Ochaion, S. Cohen, R. Patoka, G. Zozulya, F. Barer, E. Atar, S. Pina-Oviedo, G. Perez-Liz, D. Castel, and P. Fishman. Induction of an Antiinflammatory Effect and Prevention of Cartilage Damage in at Knee Osteoarthritis by CF101 Treatment. ARTHRITIS & RHEUMATISM Vol. 60, No. 10, (2009) 3061–3071
36.
35.
34.
33.
32.
31.
30.
29.
28.
27.
26.
25.
24.
23.

Baharav, E., Bar-Yehuda, S., Madi, L., Silberman, D., Rath-Wolfson, L., Halpren, M., Ochaion, A., Weinberger, A., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models. J Rheumatol. 32:469-76. 2005.

22.
21.
20.
19.
18.
17.
16.
15.
14.
13.
12.
11.
10.
9.
8.
7.
6.
5.
4.
3.
2.
1.